Latest Drug Commercialization News

Page 1 of 1
Actinogen Medical says its pivotal XanaMIA Alzheimer’s trial remains on course for topline results in November after the final patient visit was completed. The company also reported $15.9 million in cash, a further $5.3 million from option funding and a projected runway into late 2027 or 2028, assuming future trials are substantially partner-funded.
Ada Torres
Ada Torres
19 Oct 2026
Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.
Ada Torres
Ada Torres
20 Oct 2025

Browse the archive

Full archive